We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Clostridium difficile Ribotypes Are Prevalent in European Hospitals

By LabMedica International staff writers
Posted on 29 Nov 2010
Diverse types of the bacteria Clostridium difficile are more widespread in European hospitals than was originally postulated. More...


Stool samples from patients with suspected C. difficile infection and diarrhea were tested by enzyme immunoassays (EIA), cytotoxicity test, or polymerase chain reaction (PCR) assays.

A multihospital study carried out at Leiden University Medical Center (Leiden, Netherlands; www.lumc.nl) included a network of 106 laboratories in 34 European countries. The network was set up with the aim of including one hospital for countries with fewer than two million inhabitants, three for those with between two and 20 million inhabitants, and five for those with more than 20 million inhabitants, with a balance between academic and non-academic institutions.

Patients were included in the study whose stools were positive for toxin A, B, or both or revealed the presence of toxin-producing C. difficile were defined as having C. difficile infection. Detailed information was obtained for 509 patients, and for 389 of these patients, isolates were available for characterization. Identification of C. difficile was confirmed by an in-house PCR test for the glutamate dehydrogenase gene specific to C. difficile. Isolates were further characterized by PCR ribotyping. Since PCR-ribotypes 014 and 020 are nearly identical and differ only by one band on a specific agarose-gel electrophoresis, the types were reported together as ribotype 014/020.

Sixty five different PCR ribotypes were identified, and the most prevalent types were: 014/020 from 61 patients (16%); 001 from 37 stools (9%), and 078 from 31 samples (8%) The prevalence of type 027 was 5%, with highest rates in UK and Ireland. The most infected patients had a previously identified risk profile of old age, comorbidity, and recent antibiotic use. At follow up, 101 (22%) of 455 patients had died, and C. difficile infection played a role in 40 (40%) of deaths.

The authors concluded that the incidence of C. difficile infection and the distribution of causative PCR ribotypes differed greatly between hospitals in Europe and overall attributable mortality were strikingly high. They emphasized that C. difficile infection incidence rates of participating hospitals were not representative of national incidence rates, many hospitals with high rates of C. difficile infection were from countries in northern and central Europe. Most of these countries are thought to have low antibiotic consumption per head, even during the winter respiratory infection season. The study was published online on the 15 November, 2010, in the Lancet.

Related Links:

Leiden University Medical Center



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.